Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 6/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585402 | 1.00 | STAT3 (0.43) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL585401 | 1.00 | STAT3 (0.43) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL2840345 | 0.92 | GSK3B (0.38) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL2840344 | 0.92 | GSK3B (0.38) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL2838587 | 0.90 | ADRB2 (0.47) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL584971 | 0.90 | ADRB2 (0.47) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL584970 | 0.90 | ADRB2 (0.47) | STAT3GSK3BKDM4EPOLBALDH1A1 | |
| SCHEMBL583954 | 0.90 | STAT3 (0.43) | STAT3KDM4EALDH1A1TDP1HPGD | |
| SCHEMBL585353 | 0.89 | KCNH2 (0.44) | GSK3BKDM4EPOLBALDH1A1LMNA | |
| SCHEMBL585354 | 0.89 | KCNH2 (0.44) | GSK3BKDM4EPOLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | STAT3 4545/4885GSK3B 4330/4885KDM4E 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.